Patents by Inventor Emily M. Stocking

Emily M. Stocking has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Disubstituted octahydropyrrolo[3,4-c]pyrroles as orexin receptor modulators
    Patent number: 12378254
    Abstract: Disubstituted octahydropyrrolo[3,4-c]pyrrole compounds are described, which are useful as orexin receptor modulators. Such compounds may be useful in pharmaceutical compositions and methods for the treatment of diseased states, disorders, and conditions mediated by orexin activity, such as insomnia.
    Type: Grant
    Filed: June 2, 2023
    Date of Patent: August 5, 2025
    Assignee: Janssen Pharmaceutica NV
    Inventors: Wenying Chai, Michael A. Letavic, Kiev S. Ly, Daniel J. Pippel, Dale A. Rudolph, Kathleen C. Sappey, Brad M. Savall, Chandravadan R. Shah, Brock T. Shireman, Akinola Soyode Johnson, Emily M. Stocking, Devin M. Swanson
  • Tri-substituted aryl and heteroaryl derivatives as modulators of PI3-kinase and autophagy pathways
    Patent number: 12049462
    Abstract: The present disclosure relates to tri-substituted aryl and heteroaryl derivatives. pharmaceutical compositions containing them, and methods of using them, including methods for modulating autophagy or preventing, reversing, slowing or inhibiting the PI3K-AKT-MTOR pathway, and methods of treating diseases that are associated with autophagy or the PI3K-AKT-MTOR pathway.
    Type: Grant
    Filed: November 7, 2022
    Date of Patent: July 30, 2024
    Assignee: Neuropore Therapies, Inc.
    Inventors: Emily M. Stocking, Wolfgang J. Wrasidlo
  • DISUBSTITUTED OCTAHYDROPYRROLO[3,4-C]PYRROLES AS OREXIN RECEPTOR MODULATORS
    Publication number: 20240109901
    Abstract: Disubstituted octahydropyrrolo[3,4-c]pyrrole compounds are described, which are useful as orexin receptor modulators. Such compounds may be useful in pharmaceutical compositions and methods for the treatment of diseased states, disorders, and conditions mediated by orexin activity, such as insomnia.
    Type: Application
    Filed: June 2, 2023
    Publication date: April 4, 2024
    Inventors: Wenying Chai, Michael A. Letavic, Kiev S. Ly, Daniel J. Pippel, Dale A. Rudolph, Kathleen C. Sappey, Brad M. Savall, Chandravadan R. Shah, Brock T. Shireman, Akinola Soyode Johnson, Emily M. Stocking, Devin M. Swanson
  • Substituted phenyl sulfonyl phenyl triazole thiones and uses thereof
    Patent number: 11708338
    Abstract: The present disclosure relates to substituted phenyl sulfonyl phenyl triazole thiones, pharmaceutical compositions containing them, and methods of using them.
    Type: Grant
    Filed: April 6, 2021
    Date of Patent: July 25, 2023
    Assignee: Neuropore Therapies, Inc.
    Inventors: Wolfgang J. Wrasidlo, Emily M. Stocking, Srinivasa Reddy Natala, Diana Luz Price
  • Disubstituted octahydropyrrolo[3,4-c]pyrroles as orexin receptor modulators
    Patent number: 11667644
    Abstract: Disubstituted octahydropyrrolo[3,4-c]pyrrole compounds are described, which are useful as orexin receptor modulators. Such compounds may be useful in pharmaceutical compositions and methods for the treatment of diseased states, disorders, and conditions mediated by orexin activity, such as insomnia.
    Type: Grant
    Filed: July 9, 2021
    Date of Patent: June 6, 2023
    Assignee: Janssen Pharmaceutica NV
    Inventors: Wenying Chai, Michael A. Letavic, Kiev S. Ly, Daniel J. Pippel, Dale A. Rudolph, Kathleen C. Sappey, Brad M. Savall, Chandravadan R. Shah, Brock T. Shireman, Akinola Soyode Johnson, Emily M. Stocking, Devin M. Swanson
  • Tri-substituted aryl and heteroaryl derivatives as modulators of PI3-kinase and autophagy pathways
    Patent number: 11492348
    Abstract: The present disclosure relates to tri-substituted aryl and heteroaryl derivatives, pharmaceutical compositions containing them, and methods of using them, including methods for modulating autophagy or preventing, reversing, slowing or inhibiting the PI3K-AKT-MTOR pathway, and methods of treating diseases that are associated with autophagy or the PI3K-AKT-MTOR pathway.
    Type: Grant
    Filed: April 9, 2019
    Date of Patent: November 8, 2022
    Assignee: Neuropore Therapies, Inc.
    Inventors: Emily M. Stocking, Wolfgang J. Wrasidlo
  • Compounds and compositions as modulators of TLR signaling
    Patent number: 11299487
    Abstract: The present disclosure relates to substituted aryl and heteroaryl compounds, pharmaceutical compositions comprising such compounds, and use of such compounds in methods of treatment or in medicaments for treatment of inflammatory diseases and certain neurological disorders that are related to inflammatory signaling processes, including but not limited to misfolded proteins.
    Type: Grant
    Filed: March 25, 2020
    Date of Patent: April 12, 2022
    Assignee: Neuropore Therapies, Inc.
    Inventors: Srinivasa Reddy Natala, Wolfgang J. Wrasidlo, Emily M. Stocking
  • Morpholine derivates as inhibitors of Vps34
    Patent number: 11236079
    Abstract: The present disclosure relates to thiazole- or diathiazole-substituted aryl and heteroaryl compounds (I), pharmaceutical compositions containing them, and methods of using them, including treatment of disorders or disease related to regulation of the Vps34/PI3K III signaling pathway.
    Type: Grant
    Filed: April 9, 2019
    Date of Patent: February 1, 2022
    Assignee: Neuropore Therapies, Inc.
    Inventors: Emily M. Stocking, Wolfgang J. Wrasidlo
  • Disubstituted Octahydropyrrolo[3,4-c]Pyrroles As Orexin Receptor Modulators
    Publication number: 20210347781
    Abstract: Disubstituted octahydropyrrolo[3,4-c]pyrrole compounds are described, which are useful as orexin receptor modulators. Such compounds may be useful in pharmaceutical compositions and methods for the treatment of diseased states, disorders, and conditions mediated by orexin activity, such as insomnia.
    Type: Application
    Filed: July 9, 2021
    Publication date: November 11, 2021
    Inventors: Wenying Chai, Michael A. Letavic, Kiev S. Ly, Daniel J. Pippel, Dale A. Rudolph, Kathleen C. Sappey, Brad M. Savall, Chandravadan R. Shah, Brock T. Shireman, Akinola Soyode Johnson, Emily M. Stocking, Devin M. Swanson
  • Heteroaryl amides as inhibitors of protein aggregation
    Patent number: 11078196
    Abstract: The present invention relates to certain heteroaryl amide compounds, pharmaceutical compositions containing them, and methods of using them, including methods for preventing, reversing, slowing, or inhibiting protein aggregation, and methods of treating diseases that are associated with protein aggregation, including neurodegenerative diseases such as Parkinson's disease, Alzheimer's disease, Lewy body disease, Parkinson's disease with dementia, fronto-temporal dementia, Huntington's Disease, amyotrophic lateral sclerosis, and multiple system atrophy, and cancer and melanoma.
    Type: Grant
    Filed: June 11, 2019
    Date of Patent: August 3, 2021
    Assignee: UCB Biophama SRL
    Inventors: Wolfgang Wrasidlo, Emily M. Stocking
  • Disubstituted octahydropyrrolo[3,4-C]pyrroles as orexin receptor modulators
    Patent number: 11059828
    Abstract: Disubstituted octahydropyrrolo[3,4-c]pyrrole compounds are described, which are useful as orexin receptor modulators. Such compounds may be useful in pharmaceutical compositions and methods for the treatment of diseased states, disorders, and conditions mediated by orexin activity, such as insomnia.
    Type: Grant
    Filed: October 15, 2019
    Date of Patent: July 13, 2021
    Assignee: Janssen Pharmaceutica NV
    Inventors: Wenying Chai, Michael A. Letavic, Kiev S. Ly, Daniel J. Pippel, Dale A. Rudolph, Kathleen C. Sappey, Brad M. Savall, Chandravadan R. Shah, Brock T. Shireman, Akinola Soyode Johnson, Emily M. Stocking, Devin M. Swanson
  • Substituted phenyl sulfonyl phenyl triazole thiones and uses thereof
    Patent number: 11008294
    Abstract: The present disclosure relates to substituted phenyl sulfonyl phenyl triazole thiones, pharmaceutical compositions containing them, and methods of using them.
    Type: Grant
    Filed: October 24, 2019
    Date of Patent: May 18, 2021
    Assignee: Neuropore Therapies, Inc.
    Inventors: Wolfgang J. Wrasidlo, Emily M. Stocking, Srinivasa Reddy Natala, Diana Luz Price
  • Bis-heteroaryl derivatives as modulators of protein aggregation
    Patent number: 10975066
    Abstract: The present invention relates to certain bis-heteroaryl compounds, pharmaceutical compositions containing them, and methods of using them, including methods for preventing, reversing, slowing, or inhibiting protein aggregation, and methods of treating diseases that are associated with protein aggregation, including neurodegenerative diseases such as Parkinson's disease, Alzheimer's disease, Lewy body disease, Parkinson's disease with dementia, fronto-temporal dementia, Huntington's Disease, amyotrophic lateral sclerosis, and multiple system atrophy, and cancer including melanoma.
    Type: Grant
    Filed: July 29, 2016
    Date of Patent: April 13, 2021
    Assignee: UCB Biopharma SRL
    Inventors: Wolfgang Wrasidlo, Emily M. Stocking, Adrian Hall, Malcolm Maccoss
  • Disubstituted Octahydropyrrolo[3,4-C]Pyrroles As Orexin Receptor Modulators
    Publication number: 20200048263
    Abstract: Disubstituted octahydropyrrolo[3,4-c]pyrrole compounds are described, which are useful as orexin receptor modulators. Such compounds may be useful in pharmaceutical compositions and methods for the treatment of diseased states, disorders, and conditions mediated by orexin activity, such as insomnia.
    Type: Application
    Filed: October 15, 2019
    Publication date: February 13, 2020
    Inventors: Wenying Chai, Michael A. Letavic, Kiev S. Ly, Daniel J. Pippel, Dale A. Rudolph, Kathleen C. Sappey, Brad M. Savall, Chandravadan R. Shah, Brock T. Shireman, Akinola Soyode Johnson, Emily M. Stocking, Devin M. Swanson
  • Substituted phenyl sulfonyl phenyl triazole thiones and uses thereof
    Patent number: 10501423
    Abstract: The present disclosure relates to substituted phenyl sulfonyl phenyl triazole thiones, pharmaceutical compositions containing them, and methods of using them.
    Type: Grant
    Filed: March 27, 2019
    Date of Patent: December 10, 2019
    Assignee: Neuropore Therapies, Inc.
    Inventors: Wolfgang J. Wrasidlo, Emily M. Stocking, Srinivasa Reddy Natala, Diana Luz Price
  • HETEROARYL AMIDES AS INHIBITORS OF PROTEIN AGGREGATION
    Publication number: 20190308965
    Abstract: The present invention relates to certain heteroaryl amide compounds, pharmaceutical compositions containing them, and methods of using them, including methods for preventing, reversing, slowing, or inhibiting protein aggregation, and methods of treating diseases that are associated with protein aggregation, including neurodegenerative diseases such as Parkinson's disease, Alzheimer's disease, Lewy body disease, Parkinson's disease with dementia, fronto-temporal dementia, Huntington's Disease, amyotrophic lateral sclerosis, and multiple system atrophy, and cancer and melanoma.
    Type: Application
    Filed: June 11, 2019
    Publication date: October 10, 2019
    Applicant: UCB Biopharma SPRL
    Inventors: Wolfgang WRASIDLO, Emily M. Stocking
  • Heteroaryl amides as inhibitors of protein aggregation
    Patent number: 10358443
    Abstract: The present invention relates to certain heteroaryl amide compounds, pharmaceutical compositions containing them, and methods of using them, including methods for preventing, reversing, slowing, or inhibiting protein aggregation, and methods of treating diseases that are associated with protein aggregation, including neurodegenerative diseases such as Parkinson's disease, Alzheimer's disease, Lewy body disease, Parkinson's disease with dementia, fronto-temporal dementia, Huntington's Disease, amyotrophic lateral sclerosis, and multiple system atrophy, and cancer and melanoma.
    Type: Grant
    Filed: August 1, 2017
    Date of Patent: July 23, 2019
    Assignee: UCB Biopharma SPRL
    Inventors: Wolfgang Wrasidlo, Emily M. Stocking
  • Heteroaryl amides as inhibitors of protein aggregation
    Patent number: 9738635
    Abstract: The present invention relates to certain heteroaryl amide compounds, pharmaceutical compositions containing them, and methods of using them, including methods for preventing, reversing, slowing, or inhibiting protein aggregation, and methods of treating diseases that are associated with protein aggregation, including neurodegenerative diseases such as Parkinson's disease, Alzheimer's disease, Lewy body disease, Parkinson's disease with dementia, fronto-temporal dementia, Huntington's Disease, amyotrophic lateral sclerosis, and multiple system atrophy, and cancer and melanoma.
    Type: Grant
    Filed: December 29, 2015
    Date of Patent: August 22, 2017
    Assignee: NEUROPORE THERAPIES, INC.
    Inventors: Wolfgang Wrasidlo, Emily M. Stocking
  • Disubstituted Octahydropyrrolo[3,4-C]Pyrroles As Orexin Receptor Modulators
    Publication number: 20170129901
    Abstract: Disubstituted octahydropyrrolo[3,4-c]pyrrole compounds are described, which are useful as orexin receptor modulators. Such compounds may be useful in pharmaceutical compositions and methods for the treatment of diseased states, disorders, and conditions mediated by orexin activity, such as insomnia.
    Type: Application
    Filed: January 24, 2017
    Publication date: May 11, 2017
    Inventors: Wenying Chai, Michael A. Letavic, Kiev S. Ly, Daniel J. Pippel, Dale A. Rudolph, Kathleen C. Sappey, Brad M. Savall, Chandravadan R. Shah, Brock T. Shireman, Akinola Soyode Johnson, Emily M. Stocking, Devin M. Swanson
  • Disubstituted octahydropyrrolo[3,4-c]pyrroles as orexin receptor modulators
    Patent number: RE48841
    Abstract: Disubstituted octahydropyrrolo[3,4-c]pyrrole compounds are described, which are useful as orexin receptor modulators. Such compounds may be useful in pharmaceutical compositions and methods for the treatment of diseased states, disorders, and conditions mediated by orexin activity, such as insomnia.
    Type: Grant
    Filed: April 23, 2019
    Date of Patent: December 7, 2021
    Assignee: Janssen Pharmaceutica NV
    Inventors: Wenying Chai, Michael A. Letavic, Kiev S. Ly, Daniel J. Pippel, Dale A. Rudolph, Kathleen C. Sappey, Brad M. Savall, Chandravadan R. Shah, Brock T. Shireman, Akinola Soyode-Johnson, Emily M. Stocking, Devin M. Swanson